Molecular biology has come of age.
As genetic manipulation and cloning are transformed from obscure laboratory techniques to trials, multi-million pound companies are rapidly emerging to exploit the commercial potential. But how real is this potential? And can the 'unholy alliance' of academe and business survive the demands of each?
John Maddox talks to Dr Charles Weissmann of the University of Zurich, who has a foot in each camp.